Explainer: a new nanochip that will detect bacteri
Post# of 22465
Posted On: 10/20/2015 2:38:37 PM
Explainer: a new nanochip that will detect bacterial infections in 15 minutes
http://theconversation.com/explainer-a-new-na...utes-48940
.....wonder what's up w/NanoAxis
Chakravarthy: edging toward breakthroughs in nanomedicine
"Over the course of six years, our business goals have shifted from large-scale nano materials manufacturing to being the world leader in developing paradigm-shifting technologies in the field of nano medicine."
http://inbt.jhu.edu/2015/02/09/chakravarthy-e...omedicine/
NanoAxis And Avanti Therapeutics Will Jointly Launch NanoAxis Neurosciences
Baltimore, MD, February 11, 2015 – NanoAxis and Avanti Therapeutics will jointly launch NanoAxis Neurosciences to be located in the state of Maryland. The partnership will incorporate Avanti programmable therapeutic platform to advance drug and gene therapy development and discovery for central nervous system diseases currently in NanoAxis pipeline. According to current market reports, the blood brain barrier market will reach half-billion by 2019, with a compounded average growth rate of 65%. NanoAxis Neurosciences poises to be an early entrant in an expanding market. The jointly developed technology will allow selective gene and drug targeting in the brain. NanoAxis Neurosciences will develop its Alzheimer’s program as its lead candidate. The Alzheimer’s drug market peaked last year at $10.2 billion.
Other viable preclinical programs in the NanoAxis neuroscience pipeline will target Epilepsy, Depression, and Chronic Pain. The programmable therapeutic model will advance the personalized medical care evolution that is taking place in healthcare. The combination platform will allow for patient treatment tailored to their specific needs by a combination of sophisticated engineering principles that will start at the nano-level. The therapy will not only be unique in its biological targets for each disease process, but by being patient-oriented, it will allow increased compliance, decreased side effects, and rapid recovery and treatment. “Our approach with Avanti will be radically different than other companies developing Alzheimer’s gene and drug therapy candidates out there. Alzheimer’s disease is a growing problem, and the number of affected people will continue to see a rapid rise as better diagnostic tools are going to be developed. With generic alternatives on the way, our technology has a lot of scientific and commercial potential and promise. Avanti has shown their platform works in the cancer area and are beginning clinical trials, we hope to develop a parallel approach in the neuroscience front."
http://www.biospace.com/News/nanoaxis-and-ava...tly/365950
http://www.avantitherapeutics.com/Products/P-index.html
Sept 20, 2011
Quantum Materials Corp. and Nanoaxis, LLC announce the formation of a technology alliance combining Quantum Materials tetrapod quantum dot mass production technology with Nanoaxis advanced research expertise and intellectual property in gene therapy biomedical nanotechnology. The aim of the alliance is to develop Tetrapod Quantum Dot based Cancer diagnostic kits and theranostic applications including Alzheimer's, Type 1 and Type 2 Diabetes, Breast Cancer and Major Depression.
http://www.prnewswire.com/news-releases/quant...98673.html
From NanoAxis website:
"NanoAxis and QTM corporation are working together to intergrate mass manufacturing capability of tetrapod Quantum Dots into our nano-medical applications."
http://nanoaxisllc.com/Collaborators.html
Looking Forward
http://theconversation.com/explainer-a-new-na...utes-48940
.....wonder what's up w/NanoAxis
Chakravarthy: edging toward breakthroughs in nanomedicine
"Over the course of six years, our business goals have shifted from large-scale nano materials manufacturing to being the world leader in developing paradigm-shifting technologies in the field of nano medicine."
http://inbt.jhu.edu/2015/02/09/chakravarthy-e...omedicine/
NanoAxis And Avanti Therapeutics Will Jointly Launch NanoAxis Neurosciences
Baltimore, MD, February 11, 2015 – NanoAxis and Avanti Therapeutics will jointly launch NanoAxis Neurosciences to be located in the state of Maryland. The partnership will incorporate Avanti programmable therapeutic platform to advance drug and gene therapy development and discovery for central nervous system diseases currently in NanoAxis pipeline. According to current market reports, the blood brain barrier market will reach half-billion by 2019, with a compounded average growth rate of 65%. NanoAxis Neurosciences poises to be an early entrant in an expanding market. The jointly developed technology will allow selective gene and drug targeting in the brain. NanoAxis Neurosciences will develop its Alzheimer’s program as its lead candidate. The Alzheimer’s drug market peaked last year at $10.2 billion.
Other viable preclinical programs in the NanoAxis neuroscience pipeline will target Epilepsy, Depression, and Chronic Pain. The programmable therapeutic model will advance the personalized medical care evolution that is taking place in healthcare. The combination platform will allow for patient treatment tailored to their specific needs by a combination of sophisticated engineering principles that will start at the nano-level. The therapy will not only be unique in its biological targets for each disease process, but by being patient-oriented, it will allow increased compliance, decreased side effects, and rapid recovery and treatment. “Our approach with Avanti will be radically different than other companies developing Alzheimer’s gene and drug therapy candidates out there. Alzheimer’s disease is a growing problem, and the number of affected people will continue to see a rapid rise as better diagnostic tools are going to be developed. With generic alternatives on the way, our technology has a lot of scientific and commercial potential and promise. Avanti has shown their platform works in the cancer area and are beginning clinical trials, we hope to develop a parallel approach in the neuroscience front."
http://www.biospace.com/News/nanoaxis-and-ava...tly/365950
http://www.avantitherapeutics.com/Products/P-index.html
Sept 20, 2011
Quantum Materials Corp. and Nanoaxis, LLC announce the formation of a technology alliance combining Quantum Materials tetrapod quantum dot mass production technology with Nanoaxis advanced research expertise and intellectual property in gene therapy biomedical nanotechnology. The aim of the alliance is to develop Tetrapod Quantum Dot based Cancer diagnostic kits and theranostic applications including Alzheimer's, Type 1 and Type 2 Diabetes, Breast Cancer and Major Depression.
http://www.prnewswire.com/news-releases/quant...98673.html
From NanoAxis website:
"NanoAxis and QTM corporation are working together to intergrate mass manufacturing capability of tetrapod Quantum Dots into our nano-medical applications."
http://nanoaxisllc.com/Collaborators.html
Looking Forward
(0)
(0)